Gamma Delta T Cell Adjuvant for Cancer

Gamma delta (γδ) T cells function at the interface between the innate and adaptive immune systems and can be harnessed to augment the immune response to cancer and infectious disease. By combining a caspase inhibitor with a cancer antigen, this cancer specific adjuvant composition can produce a γδ driven immune response expanding the T cell response to that cancer. These methods can also be used to promote immune responses against infectious disease agents, especially those agents that induce long term chronic infections, such as Lyme disease.

Applications:
- Cancer and infectious disease immunotherapy adjuvants.

Advantages:
- Captures cellular stress via induced cell death to augment the adaptive response
- Expands the spectrum of T cell response to cancer and infectious disease.
- Cancer specific compositions can provide personalized adjuvants

Intellectual Property and Development Status:
US Patent No. 9,925,230; US Non-Provisional Application 15/892,280
Looking for research and development collaboration and licensing opportunities.

References:

Inventors:
Ralph Budd

Contact Information:
Kerry Elizabeth Swift
Technology Licensing Officer
Kerry.Swift@med.uvm.edu
802-656-8780